[The etiology of 340 infants with early-onset epilepsy]

T Y Song1, J Deng1, F Fang1

  • 1Department of Neurology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China.

Insights

Genetic factors are the most common cause of epilepsy in infants under six months old. Early genetic testing aids in identifying causes and guiding treatment for early-onset epilepsy.

Area of Science:

  • Pediatric Neurology
  • Clinical Genetics
  • Epileptology

Background:

  • Epilepsy onset in early infancy (0-6 months) presents diagnostic challenges.
  • Understanding the etiology of early-onset epilepsy is crucial for effective management.

Purpose of the Study:

  • To investigate the causes of epilepsy presenting before 6 months of age.
  • To enhance clinical comprehension of early-infantile epilepsy etiology.

Main Methods:

  • Retrospective analysis of clinical data from 340 infants with epilepsy onset <6 months.
  • Inclusion of medical history, EEG, brain imaging, and genetic testing results.
  • Statistical comparison of onset ages across different etiological groups using the Rank Sum test.

Main Results:

  • Genetic etiology was identified in 23.2% of patients, being the most common defined cause.
  • Genetic testing revealed pathogenic variants in 41.2% of tested individuals.
  • Metabolic etiology showed an earlier onset age compared to structural etiology (P=0.044).

Conclusions:

  • Genetic factors represent the leading identified etiology for epilepsy in infants aged 0-6 months.
  • Distinct age-of-onset patterns exist among different epilepsy etiologies.
  • Genetic testing is valuable for etiology identification and treatment guidance in early-onset epilepsy.

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
686
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
871
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
894
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
484
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
572